Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their ordinary shareholdings.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The material change disclosed is an increase in the ordinary share interests of ten company executives and directors. These increases resulted from the re-investment of dividends paid to shareholders on January 5, 2012. The shares were purchased at a price of 1,445.87 pence per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: January 5, 2012.
- Share Price: 1,445.87 pence per share.
- Transaction Type: Dividend re-investment leading to increased holdings.
- Participants: Dr M M Slaoui, Mr S M Bicknell, Mr J M Clarke, Mr M Dunoyer, Mr E J Gray, Mr S A Hussain, Mr D S Redfern, Mr J R Stéphenne, Ms C Thomas, Mr P C Thomson, and Dr P J T Vallance.
- Notification Date: The company was advised of these transactions on January 13, 2012.